The prognosis of an individual with a glioblastoma who receives a standard treatment is a life expectancy of around two or three years, according to the American Brain Tumor Association. However, not all glioblastomas are the same, and an individual's prognosis depends greatly on how that individual responds to treatment.
Patients who have a more aggressive form of glioblastoma have a median survival rate of about 14.6 months when treated with concurrent temozolamide and radiation therapy, according to the American Brain Tumor Association. Thirty percent of those individuals survive at least two years, and around 10 percent survive five years or longer. Also, children have a higher survival rate when compared to adults, with 25 percent of children with high-grade glioblastoma surviving five years or longer.
Other treatments, such as methylation, may increase a patient's survival rate and prolong life, according to the American Brain Tumor Association. Methylation is a process that doctors use to shut off a patient's MGMT gene, which is thought to be a major predictor of response in patients with glioblastoma. Also, as of 2015, scientists continue to study characteristics of individuals who are long-term survivors of the disease and how to better personalize individual treatments. One such emerging study is research into the tumor's molecular signature. Studying this has the potential to contribute to the prediction of the course of the disease, which could lead to improved diagnoses and prognoses.